BioSpace News Archive

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study.

Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the first quarter of 2021 after the close of market on Monday, May 10. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Michael Fisher, president and CEO of Cincinnati Children’s Hospital Medical Center, announced he intends to retire after leading the health care system for nearly 12 years.

Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 4, 2021.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, April 28. Wednesday April 28th @ 4:30pm ET

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the closing of its initial public offering of 7,567,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 987,000 additional shares of common stock, at the initial public offering price of $20.00 per share.

22nd Century Group, Inc., a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very-low nicotine content tobacco, and hemp/cannabis research, reports that it is fully prepared to partner with the U.S. Food and Drug Administration to launch its VLN® reduced nicotine content cigarette brand and license its reduced nicotine content tobacco technology to every cigarette manufacturer.

Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline’s Advair Diskus®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.

- New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia -

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1:30 p.m. PT .